7 results
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
best prevented by using ... intraocular levels of drug ... #Treatment #management ... #opportunistic ... #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
please refer to Table ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Varicella Zoster Virus (VZV) Infections in HIV-AIDS
Pre-Exposure Prevention of VZV
Recommendations for Preventing ... Pre-Exposure Prevention ... #Treatment #management ... #opportunistic ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
mucosal #IDSA #Prevention ... #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
Please refer to the table ... Tuberculosis #TB #IDSA #Prevention ... #Treatment #management ... #opportunistic ... #pharmacology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
Herpes Simplex Virus ... HerpesSimplex #HSV #IDSA #Prevention ... #Treatment #management ... #opportunistic ... #pharmacology
IDSA Recommendations for Preventing and Treating Histoplasma Capsulatum Infections in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
Recommendations for Preventing ... with ARV (see Table ... #Treatment #management ... #opportunistic ... #pharmacology